|
|
|
| Application effect of Human Blood Immunoglobulin on patients with autoimmune encephalitis and its influence on their immune level and mortality |
| YANG Chao1 GUO Xiao-bing2 JIA Xiang-dong3 |
1.Department of Neurology, Nanyuan Hospital of Fengtai District in Beijing City, Beijing 100076, China;
2.Department of Outpatient, Beijing Anding Hospital of Capital Medical University, Beijing 100088, China;
3.Epilepsy Center, the First Affiliated Hospital of PLA General Hospital (formerly 304 Hospital), Beijing 100037, China |
|
|
|
|
Abstract Objective To investigate the application effect of Human Blood Immunoglobulin on patients with autoimmune encephalitis and its influence on their immune level and mortality.Methods Forty-two patients with autoimmune encephalitis admitted to Beijing Nanyuan Hospital and the First Affiliated Hospital of PLA General Hospital from May 2015 to May 2017 were enrolled in the study.They were divided into the control group (21 cases) and the observation group (21 cases) according to the random number formula.The patients in the control group were treated with Methylprednisolone (Sou-Medrol) for 3 weeks, and the patients in the observation group were treated with Human Blood Immunoglobulin for 3 weeks on the basis of the control group.After the treatment, the cognitive level of the patients was assessed by the mini-mental state examination (MMSE).The cell levels of CD3+, CD4+, CD8+ and CD4+/CD8+ were measured by flow cytometry before and 3 weeks after treatment.The levels of procalcitonin (PCT), interferon-γ (INFγ), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay before and 3 weeks after treatment in both groups.The patients were followed up for 12 months, and the mortality was counted between the two groups.Results The MMSE scores of the two groups at 1, 2, and 3 weeks after treatment were significantly higher than those before treatment, and the differences were statistically significant (P<0.05).The MMSE scores in the observation group at 1, 2, and 3 weeks after treatment were significantly higher than those in the control group, and the differences were statistically significant (P<0.05).The cell levels of CD3+, CD4+, CD4+/CD8+in the two groups at 3 weeks after treatment were significantly higher than those before treatment, and the cell level of CD8+was significantly lower than that before treatment, with statistically significant differences (P<0.05).The cell levels of CD3+, CD4+, CD4+/CD8+ in the observation group at 3 weeks after treatment were significantly higher than those in the control group, and the cell level of CD8+ was significantly lower than that in the control group, with statistically significant differences (P<0.05).The levels of PCT, INF-γ, IL-6 and TNF-α in the two groups at 3 weeks after treatment were significantly lower than those before treatment, and the differences were statistically significant (P<0.05).The levels of PCT, INF-γ, IL-6 and TNF-α in the observation group at 3 weeks after treatment were significantly lower than those in the control group, and the differences were statistically significant (P<0.05).The mortality of the observation group at 4, 8 and 12 months after treatment was lower than that of the control group, and the difference was statistically significant (P<0.05).Conclusion The usage of Human Blood Immunoglobulin in patients with autoimmune encephalitis contrubites to enhance the function of immunity, improve the cognition function of patients, and reduce the inflammatory factor levels and the mortality.
|
|
|
|
|
|
|
|
|
